Toric IOL improves patient quality of life

Article

Implantation of a toric IOL results in improved patient quality of life and better visual, refractive and aberrometric results, states a new investigation.

Implantation of a toric IOL results in improved patient quality of life and better visual, refractive and aberrometric results, states a new investigation.

A team headed by Dr R. Mencucci, Department of Specialised Surgical Sciences–Eye Clinic, University of Florence, Florence, Italy, assessed three groups of subjects who underwent unilateral cataract surgery with IOL implantation.

The first group consisted of 40 patients with corneal astigmatism greater than 1.5 D implanted with an Acysof toric SN60TT IOL. Group two included 40 astigmatic patients implanted with the SN60AT IOL and group three included 40 patients with an astigmatism of less than 1.00 D implanted with an SB60AT IOL.

The outcome measures were uncorrected distance visual acuity (UDVA), refraction, lower order astigmatism, Strehl ratio and the modulation transfer function area ratio assessed over a three-month follow-up period. The group used a standardised quality of life test to assess both astigmatic groups three months postoperatively.

Postoperative UDVA and aberrometric values were significantly better in the toric and control group, compared with the SN60AT group. The mean postoperative spherical equivalent was significantly lower in the toric and control groups, compared to the SN60AT group.

Overall, the toric lens resulted in a better postoperative quality of life compared to the astigmatic SN60AT lens in astigmatic patients.

Please visit the British Journal of Ophthalmology to read the abstract.

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.